Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 05, 2021 08:00 ET | Source: Brickell Biotech, Inc.

Brickell Biotech To Host Key Opinion Leader Webinar on the Hyperhidrosis Market

BOULDER, Colo., March 05, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated...
February 25, 2021 16:05 ET | Source: Brickell Biotech, Inc.

Brickell Biotech to Participate in March Virtual Investor Conferences

BOULDER, Colo., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated...
February 23, 2021 16:01 ET | Source: Brickell Biotech, Inc.

Brickell Biotech to Report Fourth Quarter and Full Year 2020 Financial Results and Provide a Corporate Update on March 9, 2021

BOULDER, Colo., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated...
January 19, 2021 07:00 ET | Source: Brickell Biotech, Inc.

Brickell Biotech Announces Publication of Japan Pivotal Phase 3 Study Results for Sofpironium Bromide Gel, 5% (ECCLOCK®) in the Journal of Dermatology

BOULDER, Colo., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated...
December 07, 2020 07:30 ET | Source: Brickell Biotech, Inc.

Brickell Biotech Doses First Patient in Second U.S. Pivotal Phase 3 Clinical Study

Topline results from the U.S. pivotal Phase 3 program anticipated in the fourth quarter of 2021Sofpironium bromide gel, 5% (ECCLOCK®) recently launched in Japan by development partner, Kaken...
November 18, 2020 07:00 ET | Source: Brickell Biotech, Inc.

Brickell Biotech Announces Launch Date for Sofpironium Bromide Gel, 5% (ECCLOCK®) in Japan by its Development Partner, Kaken Pharmaceutical

Kaken plans to launch ECCLOCK® for the treatment of primary axillary hyperhidrosis in Japan on November 26, 2020- - -ECCLOCK® placed on Japan’s National Health Insurance (NHI) drug reimbursement price...
November 16, 2020 08:00 ET | Source: Brickell Biotech, Inc.

Brickell Biotech to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference

BOULDER, Colo., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated...
November 12, 2020 16:01 ET | Source: Brickell Biotech, Inc.

Brickell Biotech Reports Third Quarter 2020 Financial Results and Provides Corporate Update

Recently completed capital raise expected to fully fund U.S. pivotal Phase 3 program, with topline results anticipated in Q4 2021- - -Initiated the Cardigan I study, the first of two U.S. pivotal...
October 29, 2020 08:00 ET | Source: Brickell Biotech, Inc.

Brickell Biotech to Report Third Quarter 2020 Financial Results and Provide a Corporate Update on November 12, 2020

BOULDER, Colo., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated...
October 22, 2020 20:00 ET | Source: Brickell Biotech, Inc.

Brickell Biotech Announces Pricing of $15.0 Million Underwritten Public Offering

BOULDER, Colo., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated...